- Home
- MOLN vs ACIU Comparison
MOLN vs ACIU Comparison
Compare MOLN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- ACIU
- Stock Information
- Founded
- MOLN 2004
- ACIU 2003
- Country
- MOLN Switzerland
- ACIU Switzerland
- Employees
- MOLN N/A
- ACIU N/A
- Industry
- MOLN
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- ACIU Health Care
- Exchange
- MOLN Nasdaq
- ACIU Nasdaq
- Market Cap
- MOLN 183.2M
- ACIU 173.7M
- IPO Year
- MOLN 2021
- ACIU 2016
- Fundamental
- Price
- MOLN $4.10
- ACIU $1.68
- Analyst Decision
- MOLN
- ACIU Strong Buy
- Analyst Count
- MOLN 0
- ACIU 2
- Target Price
- MOLN N/A
- ACIU $10.00
- AVG Volume (30 Days)
- MOLN 25.8K
- ACIU 133.4K
- Earning Date
- MOLN 03-06-2025
- ACIU 04-30-2025
- Dividend Yield
- MOLN N/A
- ACIU N/A
- EPS Growth
- MOLN N/A
- ACIU N/A
- EPS
- MOLN N/A
- ACIU N/A
- Revenue
- MOLN $5,484,562.00
- ACIU $32,014,254.00
- Revenue This Year
- MOLN N/A
- ACIU N/A
- Revenue Next Year
- MOLN $866.67
- ACIU $676.94
- P/E Ratio
- MOLN N/A
- ACIU N/A
- Revenue Growth
- MOLN N/A
- ACIU 91.20
- 52 Week Low
- MOLN $3.36
- ACIU $1.43
- 52 Week High
- MOLN $12.70
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- MOLN 52.08
- ACIU 46.75
- Support Level
- MOLN $3.79
- ACIU $1.55
- Resistance Level
- MOLN $4.27
- ACIU $1.79
- Average True Range (ATR)
- MOLN 0.27
- ACIU 0.10
- MACD
- MOLN 0.04
- ACIU 0.03
- Stochastic Oscillator
- MOLN 66.07
- ACIU 66.67
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.